CCM
IGMS

Copernicus Capital Management’s IGM Biosciences IGMS Stock Holding History

Copernicus Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,000
Closed -$353K – 17
2020
Q4 		$353K Buy
+4,000
New +$281K 5.5% 8

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Copernicus Capital Management's IGMS Position: Q1 2021 in Review

Copernicus Capital Management sold out of IGM Biosciences (IGMS) in Q1 2021, closing a stake of 4,000 shares — an estimated $353K sold.

Copernicus Capital Management first reported a position in IGMS in Q4 2020 and held it in 1 quarter. The position peaked at $353K in Q4 2020. 109 funds tracked by Wall St. Rank hold IGMS as of Q1 2021.

  • Copernicus Capital Management reported no remaining IGM Biosciences position as of Q1 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 4,000 IGM Biosciences shares in Q1 2021, an estimated $353K.
  • Copernicus Capital Management first reported a position in IGM Biosciences in Q4 2020 and held it in 1 quarter.
  • Copernicus Capital Management's IGM Biosciences position peaked at $353K in Q4 2020.
  • 109 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2021.

Based on Copernicus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.